{"id":"azd-1775","safety":{"commonSideEffects":[{"rate":"30%","effect":"Thrombocytopenia"},{"rate":"25%","effect":"Neutropenia"},{"rate":"20%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL1976040","moleculeType":"Small molecule","molecularWeight":"500.61"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"By inhibiting Wee1 kinase, AZD1775 prevents the phosphorylation of cyclin-dependent kinases, leading to cell cycle arrest and apoptosis in cancer cells with compromised DNA repair mechanisms.","oneSentence":"AZD1775 is a selective inhibitor of the Wee1 kinase, which plays a critical role in cell cycle regulation and DNA damage response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T04:57:45.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT02101775","phase":"PHASE2","title":"Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-21","conditions":"Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma","enrollment":124},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT02617277","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-12-28","conditions":"Advanced Solid Tumours","enrollment":56},{"nctId":"NCT02513563","phase":"PHASE2","title":"AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2015-10-13","conditions":"Lung Cancer","enrollment":42},{"nctId":"NCT03579316","phase":"PHASE2","title":"Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-07","conditions":"Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma","enrollment":96},{"nctId":"NCT02381548","phase":"PHASE1","title":"Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","enrollment":20},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT03668340","phase":"PHASE2","title":"AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-10-22","conditions":"Uterine Cancer","enrollment":49},{"nctId":"NCT02546661","phase":"PHASE1","title":"Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2016-12-28","conditions":"Muscle Invasive Bladder Cancer","enrollment":117},{"nctId":"NCT04439227","phase":"PHASE2","title":"Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-13","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":35},{"nctId":"NCT03284385","phase":"PHASE2","title":"Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-29","conditions":"Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":60},{"nctId":"NCT04197713","phase":"PHASE1","title":"Testing the Sequential Combination of the Anti-cancer Drugs Olaparib Followed by Adavosertib (AZD1775) in Patients With Advanced Solid Tumors With Selected Mutations and PARP Resistance, STAR Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-30","conditions":"Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":13},{"nctId":"NCT02659241","phase":"EARLY_PHASE1","title":"Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-02-04","conditions":"Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma","enrollment":38},{"nctId":"NCT04460937","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-04-09","conditions":"Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8","enrollment":4},{"nctId":"NCT01849146","phase":"PHASE1","title":"Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-24","conditions":"Glioblastoma, Recurrent Glioblastoma","enrollment":74},{"nctId":"NCT03028766","phase":"PHASE1","title":"WEE1 Inhibitor with Cisplatin and Radiotherapy: a Trial in Head and Neck Cancer","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2017-06-22","conditions":"Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Larynx Cancer","enrollment":9},{"nctId":"NCT02937818","phase":"PHASE2","title":"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-28","conditions":"Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma","enrollment":72},{"nctId":"NCT03345784","phase":"PHASE1","title":"Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-29","conditions":"Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm","enrollment":10},{"nctId":"NCT01922076","phase":"PHASE1","title":"Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-09-03","conditions":"Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma, Diffuse Intrinsic Pontine Glioma","enrollment":46},{"nctId":"NCT03253679","phase":"PHASE2","title":"AZD1775 in Treating Patients With Advanced Refractory Solid Tumors With CCNE1 Amplification","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2019-01-16","conditions":"Advanced Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm","enrollment":31},{"nctId":"NCT02272790","phase":"PHASE2","title":"Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-30","conditions":"Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation","enrollment":95},{"nctId":"NCT01827384","phase":"PHASE2","title":"MPACT Study to Compare Effects of Targeted Drugs on Tumor Gene Variations","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-07","conditions":"Advanced Malignant Solid Neoplasm","enrollment":208},{"nctId":"NCT02095132","phase":"PHASE1, PHASE2","title":"Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-28","conditions":"Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma","enrollment":76},{"nctId":"NCT01357161","phase":"PHASE2","title":"A Study of Adavosertib (MK-1775) in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone for Participants With Platinum-Sensitive Ovarian Tumors With the P53 Gene Mutation (MK-1775-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-07-26","conditions":"Ovarian Cancer","enrollment":136},{"nctId":"NCT01047007","phase":"PHASE1","title":"A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-01-18","conditions":"Solid Tumors","enrollment":11},{"nctId":"NCT00648648","phase":"PHASE1","title":"A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-02-25","conditions":"Solid Tumors","enrollment":206},{"nctId":"NCT01076400","phase":"PHASE1, PHASE2","title":"A Study of Adavosertib (MK-1775) in Combination With Topotecan/Cisplatin in Participants With Cervical Cancer (MK-1775-008)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-05-31","conditions":"Cervical Cancer","enrollment":7},{"nctId":"NCT01164995","phase":"PHASE2","title":"Study With Wee-1 Inhibitor AZD1775 (MK-1775) and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2010-07","conditions":"Epithelial Ovarian Cancer","enrollment":24},{"nctId":"NCT04590248","phase":"PHASE2","title":"A Study of Adavosertib as Treatment for Uterine Serous Carcinoma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-11-30","conditions":"Uterine Serous Carcinoma","enrollment":109},{"nctId":"NCT02482311","phase":"PHASE1","title":"Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-07-01","conditions":"Ovarian Cancer, TNBC, SCLC, Other Solid Tumours","enrollment":92},{"nctId":"NCT02610075","phase":"PHASE1","title":"Phase Ib Study to Determine MTD of AZD1775 Monotherapy in Patients With Locally Advanced or Metastatic Solid Tumours.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-12-01","conditions":"Locally Advanced Solid Tumours, Metastatic Solid Tumours, Ovarian Cancer","enrollment":62},{"nctId":"NCT02194829","phase":"PHASE1, PHASE2","title":"Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-08-19","conditions":"Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7","enrollment":8},{"nctId":"NCT02576444","phase":"PHASE2","title":"OLAParib COmbinations","status":"TERMINATED","sponsor":"Joseph Paul Eder","startDate":"2015-11","conditions":"Cancer","enrollment":67},{"nctId":"NCT05008913","phase":"PHASE1","title":"Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-10-01","conditions":"Advanced Solid Tumors","enrollment":2},{"nctId":"NCT04949425","phase":"PHASE1","title":"A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-09-13","conditions":"Advanced Solid Tumours","enrollment":3},{"nctId":"NCT04462952","phase":"PHASE1","title":"Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-06-24","conditions":"Advanced Solid Tumours","enrollment":6},{"nctId":"NCT02448329","phase":"PHASE2","title":"Study of AZD1775 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring TP53 Mutation as a Second-line Chemotherapy","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2015-01-14","conditions":"Advanced Gastric Adenocarcinoma","enrollment":26},{"nctId":"NCT05212025","phase":"PHASE2","title":"Adavosertib and Gemcitabine in Advanced Pancreatic","status":"WITHDRAWN","sponsor":"James Cleary, MD, PhD","startDate":"2022-06","conditions":"Pancreatic Cancer","enrollment":""},{"nctId":"NCT03012477","phase":"PHASE2","title":"CISPLATIN + AZD-1775 In Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2017-01-18","conditions":"Triple-negative Metastatic Breast Cancer","enrollment":34},{"nctId":"NCT01748825","phase":"PHASE1","title":"AZD1775 for Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2012-12-19","conditions":"Solid Tumors","enrollment":67},{"nctId":"NCT02585973","phase":"PHASE1","title":"Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2015-10-26","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":12},{"nctId":"NCT02593019","phase":"PHASE2","title":"Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2015-12","conditions":"Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT02207010","phase":"EARLY_PHASE1","title":"A Phase 0 Study of AZD1775 in Recurrent GBM Patients","status":"COMPLETED","sponsor":"St. Joseph's Hospital and Medical Center, Phoenix","startDate":"2014-07","conditions":"Glioblastoma, GBM","enrollment":20},{"nctId":"NCT02906059","phase":"PHASE1","title":"Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2016-09","conditions":"Metastatic Colorectal Cancer","enrollment":7},{"nctId":"NCT03718143","phase":"PHASE2","title":"AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2019-05-08","conditions":"Myelofibroses, Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":6},{"nctId":"NCT02037230","phase":"PHASE1, PHASE2","title":"Dose Escalation Trial of AZD1775 and Gemcitabine (+Radiation) for Unresectable Adenocarcinoma of the Pancreas","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-01","conditions":"Adenocarcinoma of the Pancreas","enrollment":34},{"nctId":"NCT02511795","phase":"PHASE1","title":"AZD1775 Combined With Olaparib in Patients With Refractory Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-06","conditions":"Refractory Solid Tumours, Relapsed Small Cell Lung Cancer (SCLC)","enrollment":128},{"nctId":"NCT02666950","phase":"PHASE2","title":"WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-05-05","conditions":"Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm","enrollment":3},{"nctId":"NCT03313557","phase":"PHASE1","title":"AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-10-27","conditions":"Solid Tumors","enrollment":48},{"nctId":"NCT03333824","phase":"PHASE1","title":"Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-12-01","conditions":"Solid Tumours","enrollment":33},{"nctId":"NCT02341456","phase":"PHASE1","title":"Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-16","conditions":"Advanced Solid Tumours","enrollment":19},{"nctId":"NCT02508246","phase":"PHASE1","title":"WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-07-22","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":12},{"nctId":"NCT02688907","phase":"PHASE2","title":"Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2016-06-07","conditions":"Small Cell Lung Cancer","enrollment":7},{"nctId":"NCT03315091","phase":"PHASE1","title":"Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-29","conditions":"Solid Tumours","enrollment":31},{"nctId":"NCT02196168","phase":"PHASE2","title":"Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03","conditions":"Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma","enrollment":6},{"nctId":"NCT02791919","phase":"PHASE1","title":"Wee1 Kinase Inhibitor AZD1775 and Combination Chemotherapy in Treating Children, Adolescents and Young Adults With Relapsed or Refractory Acute Myeloid Leukemia","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2017-05-25","conditions":"CNS 2a, CNS 2b, CNS 2c","enrollment":""},{"nctId":"NCT02087241","phase":"PHASE2","title":"Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-03","conditions":"Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer","enrollment":22},{"nctId":"NCT02087176","phase":"PHASE2","title":"A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2014-03","conditions":"Previously Treated Non Small Cell Lung Cancer","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_1","status":"active","brandName":"AZD 1775","genericName":"AZD 1775","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AZD1775 is a selective inhibitor of the Wee1 kinase, which plays a critical role in cell cycle regulation and DNA damage response. Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}